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ABSTRACT Mycoplasma bovis-induced immune suppression is a major obstacle
faced by the host for controlling infections. M. bovis impairment of antigen-specific
T-cell responses is achieved through inhibiting the proliferation of peripheral blood
mononuclear cells (PBMCs). This impairment may contribute to the persistence of M.
bovis infection in various sites, including lungs, and its systemic spread to various or-
gans such as joints, with the underlying mechanisms remaining elusive. Here, we
elucidated the role of the immune-inhibitory receptor programmed death 1 (PD-1)
and its ligand (PD-L1) in M. bovis infection. Flow cytometry (FCM) analyses revealed
an upregulation of PD-L1 expression on tracheal and lung epithelial cell lines after
M. bovis infection. In addition, we found increased PD-L1 expression on purified lung
lavage macrophages following M. bovis infection by FCM and determined its local-
ization by immunofluorescence analysis comparing infected and control lung tissue
sections. Moreover, M. bovis infection increased the expression of the PD-1 receptor
on total PBMCs and in gated CD4 and CD8 T-cell subpopulations. We demon-
strated that M. bovis infection induced a significant decrease in CD4 PD-1INT and
CD8 PD-1INT subsets with intermediate PD-1 expression, which functioned as pro-
genitor pools giving rise to CD4 PD-1HIGH and CD8 PD-1HIGH subsets with high
PD-1 expression levels. We blocked PD-1 receptors on PBMCs using anti-PD-1 anti-
body at the beginning of infection, leading to a significant restoration of the prolif-
eration of PBMCs. Taken together, our data indicate a significant involvement of the
PD-1/PD-L1 inhibitory pathway during M. bovis infection and its associated immune
exhaustion, culminating in impaired host immune responses.
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Mycoplasma-related infections in cattle are ranked as a top priority globally by theOffice International des Epizooties (1). Cattle producers all over the world suffer
significant economic losses due to morbidity and mortality associated withMycoplasma
bovis infections (2). M. bovis is a small pleomorphic bacterium with no cell wall, which
affects both feedlot cattle (chronic pneumonia and polyarthritis syndrome [CPPS]) and
dairy cattle (therapy-resistant mastitis) (3). This pathogen is able to evade the host
immune system by the induction of substantial antigenic variation using its variable
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surface proteins (VSPs) (4). To date, limited success is achieved in the treatment or
control of disease associated with M. bovis due to its virulence and persistent nature,
restrictions on antimicrobial drug usage in food animals, the emergence of drug-
resistant strains (5, 6), and vaccination attempts that confer limited protection (7–9).
We know that variable outcomes of infection are significantly dependent on the
capacity of the host immune system to identify pathogens (10). Inhibition of immune
responses by invading pathogens is considered one of the fundamental reasons for
pathogens evading host immunity (11). Emerging vaccine trials have led to the
exploration of various immunosuppressive strategies that contribute to limited host
immune responses aimed at members of the CD28 receptor family such as the
programmed death 1 (PD-1 or CD279) receptor and its ligands (12). The PD-1 receptor
is broadly expressed on activated T cells, regulatory T cells, and other cells of a
hematopoietic lineage (13). The PD-1 receptor recognizes PD ligand 1 (PD-L1 or CD274)
and PD ligand 2 (PD-L2 or CD273), which are normally expressed on activated macro-
phages (M) and dendritic cells (12). Engagement of PD-1 with its ligands may lead to
the exhaustion of the effector T-cell population, resulting in limited responses to
infections or tumor cells (13, 14). It has been shown that this PD-1/PD-L1 inhibitory axis
results in the significant attenuation of T-cell receptor signaling, decreased expression
levels of autocrine and paracrine cytokines, a marked inhibition of proliferation, and
reduced cytotoxic activity (15). PD-1 upregulation leads to the immune exhaustion of
CD4 and CD8 T cells (16). Two different subset of T cells have been reported based
on their levels of expression of the PD-1 molecule as intermediate-expression PD-1INT
and high-expression PD-1HIGH T cells during chronic infections (17), where T cells can
become progressively exhausted, such as during chronic lymphocytic choriomeningitis
virus (LCMV) infection (18). Nevertheless, both PD-1INT and PD-1HIGH T cells are needed
for controlling chronic infections, but the shift from a PD-1INT T-cell subset to a
terminally differentiated PD-1HIGH T-cell subset led to poor outcomes (17). Previous
studies suggest the importance of reinvigorating mainly the PD-1INT T-cell subset by
targeted blocking in order to reduce viral infection and improve T-cell functions (19).
Various chronic lung infections in humans caused by both bacterial and viral
pathogens have exhibited the involvement of the PD-1 receptor (20–22). Similar studies
have recently investigated the PD-1 receptor-specific immunosuppressive role in vari-
ous chronic infections in cattle (16). The PD-1/PD-L1 axis has been studied for bovine
leukemia virus infection (23) and Mycoplasma bovis infection (24). Those studies sug-
gest that the PD-1/PD-L1 interaction plays a crucial role in shutting down vital functions
of antigen-specific T cells, leading to their exhaustion. In addition, it has been shown
that the engagement of either PD-1 or PD-L1 with specific blocking antibodies allowed
the restoration of T-cell functions, such as proliferation, cytokine production, and
cytotoxic capacity, in both ex vivo and in vivo models (23, 25–27).
M. bovis is capable of invading erythrocytes and peripheral blood mononuclear cell
(PBMC) subsets in vitro, causing the inhibition of their proliferation and delayed
apoptosis (28, 29). M. bovis can also invade bovine tracheal epithelial (EBTr) and bovine
lung epithelial (EBL) cells and survive in monocytes and bronchoalveolar lavage fluid
macrophages (BAL-M) (6). Previous studies by our group showed that the inhibition
of lymphocyte proliferation is a putative mechanism employed by M. bovis for immune
evasion (29). Based on those observations, it was interesting to further elucidate the
underlying mechanisms involved. The objective of this study is to characterize the
expression of PD-1 and PD-L1 in uninfected healthy bovine cells and in cells following
infections with M. bovis. We determined the expression levels of PD-L1 on EBTr cells,
EBL cells, and BAL-M and of PD-1 on bovine PBMC subsets. Since M. bovis infection of
PBMCs causes an inhibition of proliferation even in the presence of a potent mitogenic
signal by concanavalin A (ConA) (28), we hypothesized that blocking the interaction of
PD-1 with its ligand could help restore normal T-cell proliferation. A recent study
showed an enhancement of interferon gamma production via PD-1/PD-L1 blockade in
bovine mycoplasmosis (24), and many similar findings were reported previously for
infections by several other pathogens such as Anaplasma marginale (30), Plasmodium
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berghei (31), Mycobacterium avium subsp. paratuberculosis (26), and bovine leukemia
virus (23, 25).
Here, we report increased expression levels of PD-L1 on EBTr cells, EBL cells, and
BAL-M after M. bovis infection as determined by flow cytometry (FCM) and by
immunofluorescence (IF) staining of lung tissues. Additionally, we analyzed the differ-
entially modulated subpopulations having intermediate and high PD-1 expression
levels on both CD8 and CD4 T cells after M. bovis infection of cattle PBMCs, that
suggesting T-cell exhaustion is linked to significant decreases in CD4 PD-1INT and
CD8 PD-1INT subsets and significant increases in CD4 PD-1HIGH and CD8 PD-1HIGH
subsets. Finally, we demonstrated the restoration of the proliferation of Mb1-infected
PBMCs following a disruption of the PD-1/PD-L1 interaction using blocking anti-PD-1
antibodies. Our data will help in the development of future vaccine and therapeutic
strategies to eliminate the PD-1-related immune exhaustion of T cells during M. bovis
infection.
RESULTS
M. bovis infection augments PD-L1 expression on EBTr and EBL cell lines and
BAL-M. Our group previously described the invasion of EBTr and EBL cell lines by Mb1
(6) and found maximum invasion of both cell lines by Mb1 at 18 h of incubation.
Therefore, we decided to test the expression of PD-L1 at maximum invasion 18 h after
incubation with Mb1. Compared to the untreated controls, we found a significant
increase (P  0.05) in the expression level of PD-L1 in EBTr (Fig. 1A and B) and EBL (Fig.
1C and D) cell lines. The surface expression of PD-L1 was tested on BAL-M after 18 h
of incubation under untreated conditions, and we found that 38% of BAL-M ex-
pressed PD-L1 (Fig. 1Eii). Furthermore, we observed that the cell surface expression of
PD-L1 was increased to 55% (Fig. 1Eiii) and 79% (Fig. 1Eiv) in BAL-M infected at two
different multiplicities of infection (MOIs) of 5:1 and 100:1, respectively. A significant
increase (P  0.05) in PD-L1 expression was observed at an MOI of 100:1 compared to
untreated BAL-M (Fig. 1F).
PD-L1 localizes to lung epithelial cells and alveolar macrophages in experi-
mentally infected cattle. In alignment with the in vitro studies, we proceeded to
evaluate if PD-L1 was indeed expressed in pulmonary tissue following M. bovis infec-
tion. We localized PD-L1 in lung tissue obtained from cattle experimentally infected
with M. bovis by IF analysis. Representative IF images from one control animal and one
infected animal are shown in Fig. 2. We know from our previous experience with
multiple animal trials that lung tissues become infected by M. bovis after experimental
intranasal inoculation with a high challenge dose (7, 8, 32). Our group demonstrated
that M. bovis inoculation not only makes cattle clinically sick but also generates specific
lesions in lung tissue in response to experimental challenge (32). Hence, we performed
double-IF staining of lung tissues from these experimentally challenged cattle to
localize PD-L1 on the bovine lung epithelium as well as on alveolar M. We found that
PD-L1 was localized in lung epithelial cells as well as on alveolar M (Fig. 2B).
Furthermore, we identified alveolar M using antibody against the CD163 receptor (Fig.
2C) and colocalized IF staining in the lung tissue along with merged DAPI (4=,6-
diamidino-2-phenylindole), PD-L1, and CD163 staining (Fig. 2D). A higher magnification
of two areas of interest showed PD-L1 CD163 macrophages and some PD-L1 lung
epithelial cells (Fig. 2E and F). We also processed control lung tissue sections (not
infected by Mb1) and stained them with PD-L1 and CD163 antibodies; single stainings
with DAPI and PD-L1 and CD163 antibodies are shown in Fig. 2G to I, respectively. The
representative merged image for the control section (Fig. 2J) shows basal expression
and localization of PD-L1 CD163 macrophages and PD-L1 lung epithelial cells.
M. bovis infection upregulates the expression of PD-1 on total PBMCs and
CD4 and CD8 T cells. Our previous findings with cattle PBMCs showed that M. bovis
has the capacity to efficiently infect bovine PBMC populations, leading to an inhibition
of their proliferation (6, 28). A recent study showed increased PD-1 levels in cattle
diagnosed with mycoplasmosis (24). It was therefore necessary to further explore
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infection of bovine total PBMC populations by Mb1 at different MOIs (5:1 and 100:1).
We found that an MOI of 5:1 led to a 51% increase in PD-1 expression (Fig. 3Aiii), with
a further increase to 60% (P  0.01) (Fig. 3B) at an MOI of 100:1 (Fig. 3Aiv), whereas
untreated PBMCs exhibited basal expression of PD-1 (Fig. 3Aii), at 45%. We further
FIG 1 PD-L1 expression on EBTr and EBL cell lines and BAL-M is increased after M. bovis infection. PD-L1 expression on different cells
was tested after 18 h of incubation with or without M. bovis infection at different MOIs. (A, C, and E) FCM gating on EBTr cells (A), EBL
cells (C), and BAL-M (E) showing different conditions, including untreated and Mb1 treated cells. (B, D, and F) Graphs showing
percentages of PD-L1 expression on EBTr cells (B), EBL cells (D), and BAL-M (F). There was a significant increase in PD-L1 expression after
Mb1 infection at an MOI of 100:1. Three technical replicates were always performed under every condition in each experiment, and the
graphs indicate the medians and ranges of representative data from one of three independent experiments. Panel F shows representative
data for BAL-M collected from 3 cattle separately in three independent experiments. *, P  0.05 for significant differences in PD-L1
expression on Mb1-infected cells versus untreated cells. APC, allophycocyanin.
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investigated T-cell exhaustion caused by the cell surface upregulation of PD-1 on CD4
and CD8 T-cell populations using FCM. PBMCs were infected in vitro with Mb1 for 18
h, and FCM was performed after gating for CD4 and CD8 T cells using specific
antibodies (Fig. 4A and B). Increased expression levels of PD-1 were observed in both
CD4 and CD8 T cells (Fig. 4C and D) (P  0.01).
CD4 PD-1INT and CD8 PD-1INT subsets serve as progenitors giving rise to
CD4 PD-1HIGH and CD8 PD-1HIGH subsets. We sought to determine the origins of
the high-PD-1-expressing CD4 and CD8 T cells during the course of an established
chronic infection such as mycoplasmosis in cattle. We therefore investigated the level
of PD-1 expression on both T cell populations before and after Mb1 infection at
different MOIs (5:1 and 100:1) (Fig. 5A and B) and found distinct subsets of cells
expressing intermediate and high levels of PD-1 expression, as described previously
by others (17) (Fig. 5C). Upon further analysis, we observed gradual decreases in the cell
FIG 2 Localization of PD-L1 in bovine lung epithelial cells and alveolar macrophages of control and experimentally infected cattle. Lung tissues from one control
and three infected cattle were processed for IF localization of PD-L1. (A to C) Multicolor IF staining of infected lung sections with DAPI for nuclei (blue), the
immunoinhibitory ligand PD-L1 (green), and CD163 for alveolar macrophages (red). (D) Merge of panels A to C, with yellow arrows pointing at the colocalization
of alveolar macrophage staining for CD163 and PD-L1. (E and F) Zoom images from panel D showing higher magnifications of alveolar macrophages. (G to J)
IF staining of control uninfected lung sections for CD163 and PD-L1. Bars, 100 m (A to D and G to J) and 10 m (E and F). TB, terminal bronchiole; AD, air
duct; AS, air sac.
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populations of CD4 PD-1INT and CD8 PD-1INT subsets (Fig. 5D and F) and their
function as progenitor pools rather giving rise to CD4 PD-1HIGH and CD8 PD-1HIGH
subsets (Fig. 5E and G). Significant differences in this transition were observed at an
MOI of 100:1; however, a similar trend was observed at an MOI of 5:1.
M. bovis infection induces temporal inhibition of bovine PBMC proliferation. In
order to investigate the inhibitory effects of Mb1 on the expansion capacity of PBMCs,
we performed proliferation assays as described previously (6). There was significant
inhibition (P 0.01) when the stimulation indexes (SIs) of ConA-stimulated cells treated
or untreated with Mb1 were compared, which started as early as 24 h postinfection (Fig.
6A). Inhibition of PBMC proliferation (P  0.05) was observed at an MOI of 5:1 starting
at 48 h (Fig. 6B) and also at 72 h (Fig. 6C). The inhibition caused by Mb1 at an MOI of
100:1 persisted significantly at 48 h and 72 h (Fig. 6B and C), indicating a mechanism
of inhibition mediated by constant inhibitory signaling to PBMCs, leading to their
nonproliferative exhaustion.
M. bovis-induced inhibition of PBMC proliferation is ameliorated after blocking
PD-1. To determine whether the inhibition of PBMC proliferation, as seen in previous
studies (6, 8, 28), is dependent on the PD-1 immunoinhibitory pathway, we incubated
PBMCs with unconjugated anti-PD-1 antibody to block the PD-1 receptors. The treat-
ments included incubation with Mb1 and an anti-PD-1 antibody or an isotype control
from the start of the assays to block PD-1 during infection until the final harvest of the
cells. The experiment was performed by using Mb1 at two different MOIs, 5:1 (Fig. 6D)
and 100:1 (Fig. 6E). We observed the classical inhibition of the proliferation of ConA-
stimulated PBMCs with Mb1, which was significantly different (P  0.001) from that
under untreated (PBMCs only) ConA-stimulated conditions, whereas blockade with an
anti-PD-1 antibody led to a limited yet significant (P  0.05) restoration of the
proliferation of PBMCs infected with Mb1 at an MOI of 5:1. At the same time, infected
PBMCs incubated with an isotype control antibody showed significantly inhibited
proliferation (P 0.01) (Fig. 6D). A similar experiment was performed by using a higher
MOI of 100:1. Compared to untreated (PBMCs only) ConA-stimulated conditions, we
FIG 3 PD-1 expression is increased on bovine PBMCs after M. bovis infection. PD-1 expression on PBMCs was tested
after 18 h of incubation with or without M. bovis at different MOIs. (A) FCM gating on PBMCs showing different
conditions, including untreated cells and Mb1-treated cells at different MOIs (5:1 and 100:1). SSC, side scatter; FSC,
forward scatter. (B) Percent PD-L1 expression on PBMCs showing significant increases in PD-1 expression after Mb1
infection at an MOI of 100:1. Three technical replicates were always performed under every condition in each
experiment, and the graphs indicate the medians and ranges of representative data from one of three independent
experiments (four animals in each experiment). **, P 0.01, representing significant differences in PD-1 expression
on Mb1-infected PBMCs versus untreated cells.
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observed a more significant inhibition of the proliferation of ConA-stimulated PBMCs
after incubation with Mb1 (P  0.0001) (Fig. 6E). In addition, a significant restoration of
the proliferative properties of PBMCs was observed after blockade with an anti-PD-1
antibody (P  0.001). Moreover, restoration of proliferation was not seen after using a
specific isotype control antibody (Fig. 6E).
FIG 4 M. bovis infection of CD4 and CD8 bovine T cells increases expression of the immunoinhibitory receptor
PD-1. (A and B) PBMCs were gated and sorted to study CD4 and CD8 T cells for PD-1 expression after 18 h of
incubation with or without M. bovis at different MOIs. (C) Results showing percentages of PD-1 expression on CD4
T cells, with significant increases after Mb1 infection at an MOI of 100:1. (D) Percentages of PD-1 expression on
CD8 T cells also show a significant increase after Mb1 infection at an MOI of 100:1. Three technical replicates were
always performed under every condition in each experiment, and the graphs indicate the medians and ranges of
representative data from one of three independent experiments (four animals in each experiment). **, P  0.01,
representing significant differences in PD-1 expression on Mb1-infected cells versus untreated cells.
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FIG 5 PD-1INT T-cell subsets function as progenitor pools for PD-1HIGH T-cell subsets. The pools of exhausted T cells were analyzed to identify pre-
and postinfection changes in CD4 PD-1INT and CD8 PD-1INT subsets and also CD4 PD-1HIGH and CD8 PD-1HIGH subsets. (A and B) PBMCs were
gated and sorted to study CD4 and CD8 T cells for PD-1 expression after 18 h of incubation with or without M. bovis at different MOIs. (C)
Results showing percentages of PD-1 expression on CD4 T cells and CD8 T cells in the control and after Mb1 infection at MOIs of 5:1 and 100:1
in distinct intermediate and high subsets based on PD-1 expression. (D) Significant decrease in the percentages of CD8 PD-1INT cells after Mb1
infection (MOI of 100:1) (**, P  0.05). (E) Significant increase in the percentages of CD8 PD-1HIGH cells after Mb1 infection (MOI of 100:1)
(Continued on next page)
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The control of the PD-1/PD-L1 immune checkpoint is an important mechanism that
has been shown to remarkably modulate the adaptive immune response. In this study,
we have dissected how M. bovis regulates and exploits the PD-1/PD-L1 immune
checkpoint on multiple cell types to escape cell-mediated immunity. We further
demonstrate that the induction of this axis impairs the proliferative capacity of T cells.
Finally, we demonstrate the functional role of PD-L1-blocking antibody in disrupting
the PD-1/PD-L1 axis, thereby reversing the inhibitory effect on the T-cell-proliferative
capacity induced by M. bovis infection.
Over recent years, M. bovis has had a significant impact on the cattle industry due
to its chronic morbidity and significant mortality. This wall-less bacterial pathogen has
been known to infect both cattle and bison, causing bronchopneumonia, arthritis,
otitis, mastitis, reproductive disorders, meningitis, and conjunctivitis (33). In contrast to
its increased prevalence and distribution, mycoplasmal infections are accompanied by
a limited understanding of the mechanisms of disease resistance (34). Additionally,
several strains that have been isolated from multiple outbreaks necessitate further
inspection to understand the fundamental molecular basis of this disease (35).
Effective vaccination strategies can be derived from dissecting the mechanistic
aspects involved inM. bovis pathogenesis. An inability to recruit immune cells, impaired
clonal expansion, a loss of effector functional capacity, and the exhaustion phenotype
all appear to limit protection conferred by cell-mediated immunity, leading to persis-
tent infections culminating in chronicity and perhaps an increased incidence of tumor/
nodule development (36). Inhibitory receptors on T cells belonging to the CD28 family
have been associated with impaired cell-mediated immunity. Changes in the expres-
sion level of PD-1, a key receptor of the CD28 family, play an important role in
modulating the immune responses to intracellular infections, with different types of
viruses exploiting this pathway in order to escape immune surveillance (37).
There have been several observations that indicate impaired lymphocyte prolifera-
tion in M. bovis infections, with multiple speculations. Prior to the discovery of VSPs, a
family of surface proteins of M. bovis, it has been shown that some degree of
lymphocyte proliferation is inhibited in response to lectin mitogens with M. bovis
infection (38). Previous results from our laboratory, studying the effect of Mb1 on
lymphocyte proliferation (6), were consistent with data from a study by Thomas et al.
(39), which showed that M. bovis-infected cultures suppress phytohemagglutinin (a
nonspecific mitogen)-stimulated lymphocyte responses in a dose- and time-dependent
manner. This observed suppression was not due to differences in cell viability (28, 29).
Previous in vitro studies by Naot et al. (40) similarly investigated lymphocyte responses
to phytohemagglutinin, demonstrating a decreased proliferative capacity of lympho-
cytes in cultures inoculated with various Mycoplasma strains and species.
In line with the above-mentioned observations, we set out to investigate the source
of PD-L1, which may have implications in suppressing cell-mediated immunity. As it is
well known that M. bovis infection infects the lungs prior to systemic dissemination, we
wanted to assess its impact on cells of the pulmonary microenvironment. To this end,
our first set of in vitro studies exhibited promising results for PD-L1 induction in EBTr
and EBL cell lines (Fig. 1B and D). We further investigated the induction of the PD-1
ligand on ex vivo cattle-derived pulmonary macrophages. The Mb1 dose-dependent
increase in PD-L1 expression that was observed in these macrophages (Fig. 1F) further
incited us to affirm these findings in an actual disease setting. Accordingly, we
confirmed these observations via conducting immunofluorescence analysis of necrop-
sied pulmonary samples obtained from infected cattle (Fig. 2). In alignment with our
FIG 5 Legend (Continued)
(**, P  0.01). (F) Significant decrease in the percentages of CD4 PD-1INT cells after Mb1 infection (MOI of 100:1) (**, P  0.01). (G) Significant
increase in the percentages of CD4 PD-1HIGH cells after Mb1 infection (MOI of 100:1) (**, P  0.01). Three technical replicates were always
performed under every condition in each experiment, and the graphs indicate the medians and ranges of representative data from one of three
independent experiments (four animals in each experiment).
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FIG 6 Temporal inhibition of PBMC proliferation after M. bovis infection and its reactivation after PD-1 blockade. Bovine PBMCs were incubated
with Mb1, and incubations were performed for 24, 48, and 72 h to evaluate the temporal inhibition of proliferation under ConA-stimulated
conditions. (A to C) Significant proliferation inhibition after incubation for 24 h for ConA-stimulated PBMCs without versus those with Mb1
infection (100:1) (A) and significant proliferation inhibition after 48 h of incubation for ConA-stimulated PBMCs without versus those with Mb1
infection (MOIs of both 5:1 and 100:1) (B and C). (D) Blockade of PD-1 by anti-PD-1 antibody over the course of infection by Mb1 leads to
significant restoration of proliferation at an MOI of 5:1. (E) Similar restoration of PBMC proliferation at an MOI of 100:1. No effects were seen when
cells were incubated with an isotype control. Shown are representative data for PBMCs collected from 4 animals in three independent
experiments. Every individual animal had each treatments done in triplicates, and the bar graphs show representative data as medians and ranges
for four animals. Significant results are shown (*, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001 [for non-ConA versus ConA treatments]).
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postulate, the in vivo data endorse our in vitro and ex vivo model where M. bovis
induced PD-L1 in key cells in bovine lungs. It was shown previously that M. bovis is
known to infect hosts both intracellularly and extracellularly (41). Bovine lung macro-
phages are vital for capturing invadingM. bovis in lung tissues, and we have shown that
M. bovis is capable of not only infecting these macrophages but also surviving in them
(6). Our results demonstrated that the expression level of PD-L1 was increased in
Mb1-infected EBTr and EBL cell lines and in BAL-M at an MOI of 100:1 compared to
untreated controls. The cells that have increased expression levels of PD-L1 are also the
same cells that are the target for infection by Mb1. This novel immune evasion
mechanism may well prove to be the fundamental cause of the prolonged pathoge-
nicity of M. bovis. Moreover, the different effects of Mb1 at MOIs of 50:1 and 100:1
suggest a dose-dependent induction of PD-1 that may be a factor contributing to
variable disease outcomes. In addition, the different virulent strains of M. bovis may
account for the differential induction of PD-1 and its ligands, which may influence the
disease outcome.
Although our experimental observations clearly delineated the induction of PD-L1 in
multiple cell types in pulmonary tissue following exposure to M. bovis (Mb1), we still
were unable to ascertain its immunomodulatory role. In order to exert its effects, the
ligand needs to engage its cognate receptor PD-1 on target cells. Multiple reports of
impaired cell-mediated responses in M. bovis infections prompted us to analyze its
impact on the lymphocytic population. It is well documented that PD-1 is induced
following T-cell receptor signaling, and perhaps, its cell surface expression on activated
T cells is necessary to prevent runaway immune responses (42). The engagement of
PD-1 by its ligand (PD-L1 or -L2) inhibits proliferation and induces apoptosis in T cells
(43). Under regular conditions, it is considered a safeguard against exaggerated im-
mune responses.
Conversely, we hypothesized that the PD-1/PD-L1 pathway may be a crucial mech-
anism for immune escape if M. bovis infection induces PD-1 on effector T cells.
Consistent with our hypothesis, we observed an increase in the cell surface expression
of PD-1 on stimulated PBMCs that were exposed to Mb1 compared to the control
population (Fig. 3). We further investigated whether this observed induction impacted
helper T cells or cytotoxic T cells. Flow cytometric analysis yielded interesting results,
where both CD4 and CD8 T cells were identified as target populations that had
increased numbers of PD-1-positive cells (Fig. 4).
Chronic infection with M. bovis indicates the long-term exhaustion of immune cells,
particularly CD4 and CD8 T cells. This phenomenon has additionally been reported
for other chronic infections such as LCMV infections (18, 19) and chronic stages of
bovine Fasciola hepatica infections (44). PD-1 expression levels in CD4 and CD8 T-cell
subsets may have a significant role in progression to persistent chronic infections.
Others have demonstrated that T cells having intermediate levels of PD-1 expression
(CD4 PD-1INT and CD8 PD-1INT subsets) are progenitors of the pool giving rise to the
terminally differentiated subsets having high levels of PD-1 expression (CD4 PD-1HIGH
and CD8 PD-1HIGH subsets) (17). Interestingly, our findings show for the first time that
M. bovis infection leads to a decline in CD4 PD-1INT and CD8 PD-1INT subsets with a
concomitant increase in both the CD4 PD-1HIGH and CD8 PD-1HIGH subsets. Dimin-
ished mitochondrial and glycolytic metabolisms in CD4 PD-1HIGH and CD8 PD-1HIGH
subsets are the key factors for diminished effector functions needed by the cells to
perform optimally and counteract infection (18). A closer look at the data suggests a
substantial increase in the CD8 PD-1HIGH population compared to the CD4 PD-1HIGH
population, indicting that the effector cytotoxic T-cell response may be more signifi-
cantly impaired in a high-infectivity model (Fig. 5). Infections by Mannheimia haemo-
lytica, Histophilus somni, and Pasteurella multocida have commonly been reported with
M. bovis infections (45, 46). The observation of the nonspecific expression of PD-1 on T
cells that may disrupt their functionality may be one of the factors sustaining the
coinfections observed in these cases. The pathogenic impact ofM. bovis infection is also
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suggestive of impaired memory T-cell responses, which necessitates further investiga-
tion.
The induction of the PD-1/PD-L1 axis has multiple immunosuppressive effects;
however, the inhibition of T-cell proliferation is one of the hallmarks of this pathway.
Hence, to confirm the functional outcome, we assessed the proliferative capacity of T
cells under the influence of Mb1. As expected, the proliferation response of PBMCs was
inhibited significantly in a dose-dependent manner, which correlated well with the
induction of CD4 PD-1HIGH and CD8 PD-1HIGH subsets as described above. This loss
of proliferative capacity may be due to other suppressive pathways. To affirm the
hypothesis that the inhibition of PBMC proliferation and exhaustion of T cells by Mb1
infection are associated with the observed upregulation of the immunoinhibitory
receptor PD-1 and its ligand, we blocked the PD-1/PD ligand interaction and examined
the functional restoration of antigen-specific PBMC proliferation in vitro, which was
clearly demonstrated at an MOI of 100:1. Although the control sample with anti-PD-1
antibody-treated cells exhibited a mild, nonsignificant population expansion, we spec-
ulate that it could be due to the unopposed proliferative signaling in these cells and
linked to autoimmune responses (47). Although not assessed directly, decreased
T-helper-cell expansion could negatively influence the cytotoxic T-cell responses. In
addition, interference in the helper population could impact B-cell responses, which
may be of interest for future studies.
In light of these findings, we propose that M. bovis utilizes this pathway as a
fundamental mechanism for immune evasion by targeting immune effectors. However,
it is a valid assumption that other inhibitory pathways, such as the cytotoxic-T-
lymphocyte-associated antigen 4 (CTLA-4), indoleamine 2,3-dioxygenase (IDO), Cbl-b,
transforming growth factor  (TGF-), and interleukin-10 (IL-10) pathways, might
contribute to the development of an immune inhibition status. Interestingly, our
finding that the antibody-mediated blocking of PD-1 showed a reversal of the prolif-
erative capacity of PBMCs clearly demonstrates the irrefutable role of PD-1/PD-L1 in this
process. Although previous studies by Kinter et al. (48) demonstrate the role of
common gamma chain cytokines in the induction of PD-1, the present study was not
designed to explore the role of cytokine responses that may be involved in the
induction of PD-1. Our results, however, indicated that the PD-1/PD-L1 axis is induced
in multiple different cell types following M. bovis infection, suggesting a rather direct
role of the pathogen in orchestrating the PD-1/PD-L1 axis. The molecular pathways that
are involved in PD-1/PD-L1 axis regulation by M. bovis are of significant interest for
future studies, and the underlying molecular signaling pathways induced by M. bovis
infection may well prove to be targets for interventional therapy. It has been suggested
that reinvigorating the cells with intermediate levels of PD-1 expression (CD4 PD-1INT
and CD8 PD-1INT subsets) could be the key to effective T-cell functions. Early disease
detection followed by immune intervention may serve to reverse or limit the disease
process and is an interesting area that will be the focus of future therapeutic trials. In
addition, antibody-mediated therapy for the PD-1/PD-L1 checkpoint as an adjunct to
regular vaccines may provide a rapid solution for vaccination and have a positive
impact on the current disease burden, especially when such strategies have proven to
be beneficial in other infection models (18, 19, 27). These results imply that Mb1
orchestrates the PD-1 pathway to depress the proliferative capacity of immune cells,
thereby eluding immune detection and resulting in a delayed cell-mediated immune
response, which possibly renders the host incapable of mounting an effective immune
response.
MATERIALS AND METHODS
Bacterial stock and media. M. bovis strain Mb1, used in all experiments, was isolated from the
synovial fluid of a calf showing signs of arthritis (49). Cultures of Mb1 were grown in modified Hayflick’s
broth at 37°C with 5% CO2. Bacterial cells were collected at the exponential phase of growth and were
centrifuged at 5,500  g for 15 min, followed by washing with minimum essential medium (MEM;
Invitrogen, Burlington, ON, Canada). Mb1 bacteria were stocked at 70°C in MEM (supplemented with
30% glycerol) at a concentration of 108 CFU/ml.
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Cell lines and media. EBTr and EBL cells were obtained from the ATCC (NBL-4; ATCC CCL-44) and the
DSMZ (ACC 192), respectively. Eagle’s minimum essential medium (EMEM) (Sigma Life Science) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 g/ml streptomycin was used for EBTr
cultures, whereas RPMI 1640 supplemented with 15% FBS, 100 U/ml of penicillin, and 100g/ml streptomycin
was used for cultures of the EBL cell line. Both cell lines were cultured as described previously (6). We
evaluated cell viability using a trypan blue exclusion method as described previously (28).
PBMC purification and culture. Bovine PBMCs were isolated from blood collected in EDTA-coated
Vacutainer tubes from cattle with no history of M. bovis or other bacterial infections at the VIDO-InterVac
research farm. PBMCs were isolated as described previously (6). Briefly, cells were separated by centrif-
ugation (2,500 g for 20 min), and the buffy coat fraction containing PBMCs was purified by using Ficoll
gradients (GE Healthcare, Mississauga, ON, Canada). Culturing was done by using EMEM supplemented
with 10% FBS, 0.5 ml of 2-mercaptoethanol (50 mM), and 5 ml each of nonessential amino acids (NEAA),
sodium pyruvate (100 mM), and 1 M HEPES solution but without the addition of antibiotics. PBMCs were
washed three times with phosphate-buffered saline (PBS), followed by centrifugation (800 g for 5 min).
Cell viability was determined by using the trypan blue exclusion method as described above for EBTr and
EBL cell lines. Moreover, all PBMC samples were plated and incubated at 37°C for at least 5 days on
Hayflick’s agar (HFA) and blood agar for the detection of any M. bovis infection or contamination. The cell
samples were used only if they were M. bovis free as indicated by negative cultures.
PBMC proliferation assay. The PBMC proliferation assay was performed as described previously (6,
28). Briefly, PBMCs from individual animals were plated separately at a cell density of 3.5  105
PBMCs/well in 96-well U-bottom plates (Thermo Scientific, Denmark) in triplicates following counting on
a Coulter counter, and subsequent aliquots were also collected to determine the viability of PBMCs by
a trypan blue exclusion assay. PBMCs were infected with Mb1 at MOIs of 5:1 and 100:1 (Mb1 bacteria/
PBMCs). We used ConA (1 g/ml) as a positive control following 72 h of incubation (37°C with 5% CO2).
In addition, proliferation kinetics were conducted in triplicates at 24, 48, and 72 h. An additional
incubation for 18 h was carried out under all conditions after the addition of [3H]thymidine (0.4 Ci/well),
PBMCs were harvested (Filtermate harvester; Packard), and a scintillation counter (Top Count NXT;
Packard) was used to quantify incorporated [3H]thymidine. Proliferation results were measured as counts
per minute, shown as SIs, using the following formula: counts per minute of treated PBMCs/counts per
minute of control or unstimulated PBMCs.
BAL-M purification and culture. Lung lavage fluids were obtained from a certified local abattoir
slaughtering inspected healthy cattle, and BAL-M were purified as described previously (6). Briefly, 4
liters of Hanks’ buffered saline solution with chloramphenicol (HBSS-CMF) containing an antibiotic-
antimycotic cocktail, 10,000 U/ml of penicillin, 10 mg/ml of streptomycin, 25 g/ml of amphotericin B
(Sigma, USA), and 100 g/ml of gentamicin (Gibco, USA) was used for lung lavage. The lavage fluid was
filtered by using a 20-m-pore fabric filter, centrifuged for 10 min (400  g at 4°C), and washed twice
by using cold sterile PBS (with antibiotic-antimycotic solution). Dulbecco’s modified Eagle medium
(DMEM) supplemented with 2% FBS, 14 mM HEPES, 0.1 mM nonessential amino acids, 5 mg/ml glucose,
4 mM L-glutamine, 100 IU/ml sodium penicillin G (Gibco, USA), and an antibiotic-antimycotic solution was
used when needed. The cells were incubated for 3 h at 37°C with 5% CO2 to adhere macrophages to the
plates, the supernatant was then gently removed, and new prewarmed culture medium (without
antibiotics) was added. We tested the purity of purified BAL-M by FCM using a FACSCalibur instrument
after staining with the macrophage-specific monoclonal antibody (Serotec) (see Table S1 in the supple-
mental material) and found the purity of BAL-M to be 98% (Fig. 1Ei). We plated purified samples of
BAL-M on HFA and blood agar to exclude contaminated samples during collection and isolation.
Samples were always used from animals that were M. bovis free as indicated by negative cultures.
PD-L1 expression on EBTr cells, EBL cells, and BAL-M. PD-L1 expression after exposure to M.
bovis was determined on different cells (EBTr cells, EBL cells, and BAL-M). Flat-bottom 6-well plates
(Costar; Corning Inc., NY) were used, and 1  106 cells were infected individually with Mb1 at two
different MOIs (5:1 and 100:1) for BAL-M and at an MOI of 100:1 for EBTr and EBL cells. Uninfected
control and Mb1-infected cells were incubated for 18 h at 37°C with 5% CO2. Cells were then harvested
by using trypsin as previously described (6) and washed twice with PBS. Cells were incubated on ice with
anti-PD-L1 antibody (Santa Cruz Biotechnology Inc.) or an isotype control at a 1:50 dilution for 30 min
and later washed three times by using 200 l PBS–0.03% sodium azide (EMD Chemicals, USA).
Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit isotype-specific secondary antibody was
added (1 g/ml), and the mixture was incubated for 30 min on ice in the dark. The cells were washed
three times with PBS–0.03% sodium azide, followed by a fixation step using 2% formaldehyde (Sigma-
Aldrich). A FACSCalibur instrument (Becton Dickinson, Franklin Lakes, NJ) was used for sample acquisi-
tion, and 20,000 events were acquired with Cell Quest software (version 3.3). Later, data were analyzed
by using Kaluza software (v. 1.3).
PD-1 expression on total PBMCs, CD4 T cells, and CD8 T cells. PD-1 expression was detected
by using the FITC-conjugated anti-PD-1 antibody (Biorybt Ltd., UK). Briefly, purified PBMCs (5  105
cells/well) were incubated for 18 h at 37°C with 5% CO2 with or without Mb1 at two different MOIs (5:1
and 100:1). Cells were then centrifuged, suspended in cold PBS for labeling with anti-PD-1 antibody and
isotype control FITC-conjugated rabbit IgG antibody (Santa Cruz Inc., USA) at a 1:50 dilution, incubated
for 30 min on ice in the dark followed by two washes with PBS–0.03% sodium azide, and analyzed by
flow cytometry. For further evaluation of PD-1 expression on subpopulations of PBMCs, we performed an
experiment similar to the one described above and double stained PBMCs with anti-CD8 (1:100
dilution) and anti-CD4 (1:200 dilution) antibodies (VMRD/Kingfisher, USA), followed by their corre-
sponding secondary fluorescently labeled antibodies at a 1:100 dilution (see Table S1 in the supple-
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mental material). Flow cytometry was performed, 20,000 events were acquired, and data were analyzed
by using Kaluza and FlowJo software.
Effect on PBMC proliferation after blocking PD-1. The assay to block PD-1 expression on PBMCs
was carried out by using an unconjugated anti-PD-1 antibody (OriGene Technologies Inc., USA). The
assay was carried out as mentioned above for the PBMC proliferation assay, with a few modifications.
Briefly, PBMCs were plated (3.5  105 PBMCs/well) in triplicates and either infected by Mb1 at an MOI of
5:1 or 100:1 or stimulated with ConA (1 g/ml) as a positive control, followed by 72 h of incubation (37°C
with 5% CO2). PBMCs without any stimulation by ConA and without any M. bovis infection were used as
negative controls. At the time of infection with Mb1, cells in paired wells were treated with unconjugated
anti-PD-1 antibody (20 g/ml) or an isotype control antibody during incubation. Cells were then
incubated for 18 h after the addition of [3H]thymidine (0.4 Ci/well), and PBMCs were harvested.
Proliferation results are shown as SIs.
Immunofluorescence detection of PD-L1 in lung tissue samples from experimentally infected
cattle. Over the years, our research group has developed a highly efficient and reliableM. bovis challenge
model in cattle for studying in vivo immune responses and testing different experimental vaccines (32).
We tested lung tissue samples obtained from one naive or three M. bovis-challenged animals, and the
tissues were formalin fixed, embedded in paraffin wax, and then cut into 5-m-thick sections. The dried
sections were deparaffinized in xylene, and antigen retrieval was performed in citrate buffer (0.37 g/liter
citric acid and 2.4 g/liter trisodium citrate dihydrate) in a water bath at 95°C for 10 min. The slides were
washed with PBS for 5 min and incubated for 1 h with a multispecies 10% serum blocking solution, and
all subsequent incubations were done in the dark. Primary anti-PD-L1 antibody (see Table S1 in the
supplemental material) was used at a 1:200 dilution, and the sections were incubated for 1 h at room
temperature. An isotype control was used in parallel on similar tissue sections under similar conditions,
followed by three washes in cold PBS for 5 min each. A secondary antibody linked with FITC was added
at a 1:400 dilution for 1 h at room temperature. The sections were washed in cold PBS for 5 min each,
counterstaining was done with anti-CD163-phycoerythrin (PE) antibody (Table S1) at a 1:25 dilution, and
the sections were stained for 1 h at room temperature. The sections were washed again in cold PBS for
5 min each and mounted with medium containing DAPI for staining nuclei. The images were obtained
by using an Olympus microscope and analyzed by using ImageJ software (version 1.50i).
Statistics. A nonparametric Friedman test with Dunn’s multiple-comparison test was used to analyze
differences between median values for each group. Differences were considered significant at a P value of
0.05. Data were analyzed by using GraphPad Prism 7.00 for Windows (GraphPad Software, La Jolla, CA, USA).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/IAI
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